Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
US10647780B2 · kind B2 · utility
3Cited by
68References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 24, 2017 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Nov 6, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.